关于葡萄糖传感器设备和1型糖尿病的YouTube视频的评估:用户的感知,设备功能和内容可靠性
1Selcuk University Akşehir Kadir Yallagöz Health School, Türkiye.
Diabetes research and clinical practice
|February 26, 2025
概括
在葡萄糖传感器设备上的YouTube视频质量各不相同. 这项研究发现,详细和可靠的内容可以提高视频质量,强调需要定期评估在线健康信息.
科学领域:
- 医疗技术 医疗技术 医学技术
- 数字健康传播数字健康传播
- 内分泌学 在内分泌学.
背景情况:
- 越来越多的人依赖在线平台获取健康信息.
- 糖尿病患病率增加,需要有效的血糖监测.
- 在像YouTube这样的平台上对数字健康内容质量的有限评估.
研究的目的:
- 评估有关葡萄糖传感器设备的英语YouTube视频的性能,全面性,可靠性和质量.
- 确定关于持续血糖监测的高质量教育内容的特点.
- 为了让患者和医疗保健提供者了解YouTube对葡萄糖传感器设备信息的有用性.
主要方法:
- 在2024年11月使用与葡萄糖传感器设备相关的关键词对YouTube进行系统搜索.
- 根据预定义的包含和排除标准,对30个选定的视频进行分析.
- 数据收集包括视频性能指标 (浏览量,评论,点赞) 和内容质量评估.
主要成果:
- 40%的分析视频是由医疗保健专业人员呈现的.
- 平均视频性能指标显示了显著的参与度: 172,257 次浏览,171 次评论和 1,643 次赞.
- 40%的视频提供了良好的,有用的信息,60%的视频被评为高质量.
结论:
- 详细和可靠的内容显著提高了YouTube视频在血糖监测设备上的质量.
- 建议定期评估在线视频内容,以确保其准确性和有用性.
- 未来的研究应该探索替代测量工具和非英语语言内容,以获得更广泛的见解.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.0K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.0K
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
Diabetes: Symptoms, Diagnosis, and Complications
495
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
495
Oral Hypoglycemic Agents: Glinides
131
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
131


